Lenvatinib and Vancomycin drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Lenvatinib (lenvatinib) and Vancomycin (vancomycin). Common drug interactions include duodenal perforation among females and acute respiratory failure among males.

The phase IV clinical study analyzes what interactions people have when they take Lenvatinib and Vancomycin. It is created by eHealthMe based on reports of 7 people who take the same drugs from the FDA, and is updated regularly.

What is Lenvatinib?

Lenvatinib has active ingredients of lenvatinib. eHealthMe is studying from 3,587 Lenvatinib users. Check the latest studies of Lenvatinib.

What is Vancomycin?

Vancomycin has active ingredients of vancomycin. eHealthMe is studying from 17,165 Vancomycin users. Check the latest studies of Vancomycin.



On Jul, 21, 2026

7 people who take Lenvatinib and Vancomycin together, and have interactions are studied.

Lenvatinib and Vancomycin drug interactions.

What are the common drug interactions of Lenvatinib and Vancomycin, by gender? *:

female:

  1. Duodenal perforation (complication of duodenal ulcer)
  2. Peritonitis (inflammation of the peritoneum, the thin tissue that lines the inner wall of the abdomen and covers most of the abdominal organs)
  3. Pneumothorax (the presence of air or gas in the cavity between the lungs and the chest wall, causing collapse of the lung)
  4. Hypertension (high blood pressure)
  5. Acute respiratory failure
  6. Dyspnoea (difficult or laboured respiration)
  7. Malignant neoplasm progression (cancer tumour came back)

male:

  1. Acute respiratory failure
  2. Blood bilirubin increased
  3. Hepatic encephalopathy (spectrum of neuropsychiatric abnormalities in patients with liver failure)
  4. Lymphocyte count decreased
  5. Abdominal abscess (collection of pus in abdomen)

What are the common drug interactions of Lenvatinib and Vancomycin, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

n/a

40-49:

n/a

50-59:

  1. Peritonitis (inflammation of the peritoneum, the thin tissue that lines the inner wall of the abdomen and covers most of the abdominal organs)
  2. Duodenal perforation (complication of duodenal ulcer)

60+:

  1. Acute respiratory failure
  2. Pneumothorax (the presence of air or gas in the cavity between the lungs and the chest wall, causing collapse of the lung)
  3. Blood bilirubin increased
  4. Hepatic encephalopathy (spectrum of neuropsychiatric abnormalities in patients with liver failure)
  5. Lymphocyte count decreased
  6. Abdominal abscess (collection of pus in abdomen)
  7. Hypertension (high blood pressure)
  8. Dyspnoea (difficult or laboured respiration)
  9. Malignant neoplasm progression (cancer tumour came back)

* Approximation only. Some reports may have incomplete information.

Do you take Lenvatinib and Vancomycin?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously



Related studies:

Effectiveness of, side effects of, and alternative drugs to the 2 drugs:

Browse all drug interactions of Lenvatinib and Vancomycin:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all side effects of Lenvatinib:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all side effects of Vancomycin:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Lenvatinib and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Vancomycin and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

How the study uses the data?

The study uses data from the FDA. It is based on lenvatinib and vancomycin (the active ingredients of Lenvatinib and Vancomycin, respectively), and Lenvatinib and Vancomycin (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.



Recent studies on eHealthMe: